QLife

Qlife remains fully committed to completing the transaction and is currently pursuing alternative structures with Hipro and its advisors in order to complete the transaction as announced. Qlife and Hipro continue to work closely together in their operations and are strongly convinced that the intended transaction will create significant shareholder value, driven by the operational and strategic synergies between the companies. Qlife is dedicated to maintaining transparency and working constructively with Nasdaq to identify a compliant and sustainable solution.

Further information about the intended terms of the transaction can be found in the press releases published on 5 June and 5 October 2025: "Qlife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover" and "Qlife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended".

Further updates will be communicated as the process advances.